Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure
- 1 September 2000
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 140 (3) , 361-366
- https://doi.org/10.1067/mhj.2000.109215
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Renin-Angiotensin System, Hypertrophy and Gene Expression in Cardiac MyocytesJournal of Molecular and Cellular Cardiology, 1999
- Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytesMethods and Findings in Experimental and Clinical Pharmacology, 1999
- Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) StudyEuropean Heart Journal, 1998
- Does Blockade of Angiotensin II Receptors Offer Clinical Benefits over Inhibition of Angiotensin–Converting Enzyme?Basic & Clinical Pharmacology & Toxicology, 1998
- The Management of Chronic Heart FailureNew England Journal of Medicine, 1996
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation, 1990
- Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failureThe American Journal of Cardiology, 1990
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987